Clustered Environments and Randomized Genes: A Fundamental Distinction between Conventional and Genetic Epidemiology

George Davey Smith1,2*, Debbie A. Lawlor1,2, Roger Harbord1, Nic Timpson1,2, Ian Day1,2, Shah Ebrahim3

1 Department of Social Medicine, University of Bristol, Bristol, United Kingdom, 2 Medical Research Council Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol, United Kingdom, 3 Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom

Funding: The authors received no specific funding for this study.

Competing Interests: The authors have declared that no competing interests exist.

Academic Editor: Lon Cardon, University of Oxford, United Kingdom

Citation: Davey Smith G, Lawlor DA, Harbord R, Timpson N, Day I, et al. (2007) Clustered environments and randomized genes: A fundamental distinction between conventional and genetic epidemiology. PLoS Med 4(12): e352. doi:10.1371/journal.pmed.0040352

Received: November 17, 2006
Accepted: October 30, 2007
Published: December 11, 2007

Copyright: © 2007 Davey Smith et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: O:E, observed to expected; SNP, single nucleotide polymorphism

* To whom correspondence should be addressed. E-mail: george.davey-smith@bristol.ac.uk

ABSTRACT

Background

In conventional epidemiology confounding of the exposure of interest with lifestyle or socioeconomic factors, and reverse causation whereby disease status influences exposure rather than vice versa, may invalidate causal interpretations of observed associations. Conversely, genetic variants should not be related to the confounding factors that distort associations in conventional observational epidemiological studies. Furthermore, disease onset will not influence genotype. Therefore, it has been suggested that genetic variants that are known to be associated with a modifiable (nongenetic) risk factor can be used to help determine the causal effect of this modifiable risk factor on disease outcomes. This approach, mendelian randomization, is increasingly being applied within epidemiological studies. However, there is debate about the underlying premise that associations between genotypes and disease outcomes are not confounded by other risk factors. We examined the extent to which genetic variants, on the one hand, and nongenetic environmental exposures or phenotypic characteristics on the other, tend to be associated with each other, to assess the degree of confounding that would exist in conventional epidemiological studies compared with mendelian randomization studies.

Methods and Findings

We estimated pairwise correlations between nongenetic baseline variables and genetic variables in a cross-sectional study comparing the number of correlations that were statistically significant at the 5%, 1%, and 0.01% level (α = 0.05, 0.01, and 0.0001, respectively) with the number expected by chance if all variables were in fact uncorrelated, using a two-sided binomial exact test. We demonstrate that behavioural, socioeconomic, and physiological factors are strongly interrelated, with 45% of all possible pairwise associations between 96 nongenetic characteristics (n = 4,560 correlations) being significant at the p < 0.01 level (the ratio of observed to expected significant associations was 45; p-value for difference between observed and expected < 0.000001). Similar findings were observed for other levels of significance. In contrast, genetic variants showed no greater association with each other, or with the 96 behavioural, socioeconomic, and physiological factors, than would be expected by chance.

Conclusions

These data illustrate why observational studies have produced misleading claims regarding potentially causal factors for disease. The findings demonstrate the potential power of a methodology that utilizes genetic variants as indicators of exposure level when studying environmentally modifiable risk factors.

The Editors’ Summary of this article follows the references.
Introduction

Observational epidemiology has had notable successes, but also high-profile failures, in that it has identified many modifiable exposures apparently increasing or decreasing disease risk that have been revealed by randomized controlled trials to be noncausal [1]. The explanation in many of these cases is likely to be that confounding—by lifestyle and socioeconomic factors, or by baseline health status and treatment effects—is responsible for observed associations [2,3]. Many potentially health-modifying factors (such as use of antioxidant vitamin supplements) will be strongly related to such confounding factors [4]. Other factors that can lead to observational associations being poor predictors of causal effects include reverse causation (in which early stages of the disease process influence the exposure, rather than vice versa), imprecision in effect estimates (due to inadequate sample size), information and selection biases, and distortion of the available scientific literature that may be introduced by the processes of publication of research [5–9].

One approach to such problems in observational epidemiology is mendelian randomization [10]. The basic principle utilised in such studies is that if a genetic variant influences an environmentally modifiable risk factor that itself alters disease risk, then the genetic variant should be associated with disease risk. Further, the causal effect of the environmentally modifiable risk factor on disease risk can be calculated (under certain assumptions [11]) from the magnitude of the genetic variant’s associations with disease risk and with the environmentally modifiable risk factor. The advantage here is that the genetic variant should not be associated with the confounding lifestyle, socioeconomic, or medical care factors that distort the study of directly measured exposures and disease [10]. Furthermore, the genetic variant will not be influenced by the early stages of the disease process, and the estimate of the causal effect of interest will thus be immune to the reverse causation that can distort conventionally studied associations [5]. Observational studies of genetic variants may, therefore, have similar properties to intention-to-treat analyses aimed at determining the causal nature of a particular treatment in randomized controlled trials.

Such mendelian randomization studies have been conducted within the cardiovascular and cancer fields. This approach has provided evidence that alcohol intake increases the risk of esophageal cancer [12], and that fibrinogen and C-reactive protein appear not to increase cardiovascular disease risk or adversely influence components of the metabolic syndrome, and are therefore not suitable targets for specific pharmacotherapeutic modification [13–16]. The development of the mendelian randomization concept and the associated terminology has been discussed in detail elsewhere [17].

Despite theoretical reasons why genetic variants should be largely unrelated to many exposures or phenotypic characteristics, it has been suggested that genetic association studies in general, and mendelian randomization approaches in particular [18], are susceptible to confounding. It is suggested that confounding may occur because of the pleiotropic effect of genes (i.e., one variant affecting several phenotypes), linkage disequilibrium between the variant under study and variants influencing other phenotypes, and population substructure [10]. Pleiotropic effects would only confound associations of genotype with disease outcome if any additional pleiotropic effects of the gene were also associated with the disease outcomes of interest. Similarly, if there is linkage disequilibrium between the genotype being used as an instrument and a polymorphism that is associated with the outcome, then confounding of the gene–outcome association may occur, but if the linkage disequilibrium is with a variant that is unrelated to the outcome of interest, this will not confound the association.

Population substructure would result in confounding of the genotype–outcome association if subgroups exist within a population that have different genetic histories and different disease risks (for genetic or other reasons) as this would generate misleading associations between genetic variants and phenotypes (so-called “population stratification”). The importance of population stratification has generated a vigorous debate, but it appears that if basic precautions are applied with respect to the ethnicity and population of origin of study sample members, and appropriate analytical strategies are applied, then bias should generally be small [19–24].

Thus, we suggest that conventional observational epidemiology is particularly prone to confounding because non-genetic characteristics are highly associated with each other, perhaps even more so than is generally acknowledged. At the same time, mendelian randomization studies can exploit the general lack of associations between one genetic variant and other genetic variants, and between genetic and nongenetic variables, to provide an unconfounded estimate of the association between factors that the genetic variant directly influences and disease outcomes [10]. As discussed above, there is concern that mendelian randomization studies may, however, be confounded through pleiotropy, linkage disequilibrium, or population stratification. In truth, within the bounds of conventional epidemiological cohorts, no formal exercise has examined the extent to which genetic variants on the one hand, and nongenetic environmental exposures or phenotypic characteristics on the other, tend to be associated with each other—i.e., the degree of confounding that would exist in conventional epidemiological studies compared with mendelian randomization studies. We have therefore examined this issue empirically in the British Women’s Heart and Health Study [25].

Methods

Data from the British Women’s Heart and Health Study were used. Full details of the selection of participants and measurements, including DNA extraction and genotyping, have been previously reported [25]. Briefly, women aged 60–79 y were randomly selected from general practitioner lists in 23 British towns. A total of 4,286 women participated, and baseline data (self-completed questionnaire, research nurse interview, physical examination, and primary care medical record review) were collected between April 1999 and March 2001.

We estimated pairwise correlations between 96 nongenetic baseline variables in the study that were continuous, binary, or ordered categorical (see Text S1 for full list of these and details of whether they were continuous or how they were categorised). We compared the number of pairwise correlations that were observed to be statistically significant at the 5%, 1%, and 0.01% level ($\alpha = 0.05$, 0.01, and 0.0001, respectively) with the number expected by chance if all
variables were in fact uncorrelated, using a two-sided binomial exact test. We chose to compare observed to expected significant associations at these values of statistical significance because \( \alpha = 0.05 \) and \( \alpha = 0.01 \) are the most commonly used values in observational epidemiological studies to indicate departure from the null hypothesis, whereas for genetic associations with complex traits, much smaller \( p \)-values (of the order of 0.0001 or below) are recommended to avoid false-positive claims. By using three different values of statistical significance, we were able to determine the extent to which our results were driven by the level of significance chosen.

Three of the authors (GDS, DAL, and SE) decided a priori whether they considered that any of the nongenetic variables were measuring the same underlying characteristic or phenotype (e.g., systolic and diastolic blood pressure) or whether there were subgroups that were constituents of an overall variable (e.g., lipid subfractions and total cholesterol). Text S1 provides full details of these groups of phenotypes. In a series of sensitivity analyses, we replaced the variables used in the main analyses with other variables that we had considered to be measuring the same phenotype (e.g., replacing systolic with diastolic blood pressure; see Table S1) and replaced subgroups of variables with their overall variable (e.g., lipid subfractions by total cholesterol; see Table S2). In these sensitivity analyses, the proportion of observed statistically significant correlations (at any of \( \alpha = 5\% \), 1\%, or 0.01\%) were essentially the same as for the main results presented here. For associations between nongenetic variables, we controlled for the effect of age (because many variables will show age-related variation) by calculating age-adjusted coefficients. For the results presented here, age was treated as a continuous variable in standardised regression models. We then repeated all analyses with age entered as dummy variables (i.e., a four-category variable: 60–64, 65–69, 70–74, and 75–79 y), which does not assume that age is linearly associated with the variables. The results from these models did not differ from the models with age entered as a continuous variable.

In order to explore the extent to which the use of genetic variants as indicators of exposure levels is valid for measuring the unconfounded associations of a nongenetic risk factor with outcomes, we examined the correlations between each of 28 genetic variants and each of the 96 nongenetic characteristics. In these analyses, we also compared observed with expected statistically significant correlations at \( \alpha = 5\% \), 1\%, and 0.01\% using a two-sided binomial exact test. Results presented for these associations were not age adjusted since genetic variants should not be associated with age (and in formal tests were not; furthermore, age adjustment did not alter any results). When multiple single nucleotide polymorphisms (SNPs) were deliberately genotyped to form common haplotypes, based on existing literature about such haplotypes, only one of these SNPs (selected at random) was included in the analyses (See Table S3 for details). In a series of sensitivity analyses, we replaced the SNP selected at random with one of the other SNPs in the same haplotype block. The results from these sensitivity analyses did not differ substantively from those presented here.

Variables that were markedly positively skewed were log-transformed and categorical variables were treated as scores (see Table S1 and Text S1). All genetic variants were biallelic polymorphisms and were treated as scores from zero to two, with zero representing homozygotes for the dominant allele, one, heterozygotes, and two, homozygotes for the minor allele (see Table S3).

## Results

### Associations of Nongenetic Characteristics with Each Other

The 96 nongenetic variables generated 4,560 pairwise comparisons, of which, assuming no associations existed, five in 100 (total 228) would be expected to be associated by chance at the 5\% significance level (\( \alpha = 0.05 \)). However, 2,447 (54\%) of the correlations were significant at the \( \alpha = 0.05 \) level, giving an observed to expected (O:E) ratio of 11, \( p \) for difference O:E < 0.000001 (Table 1). At the 1\% significance level, 45.6 of the correlations would be expected to be associated by chance, but we found that 2,036 (45\%) of the pairwise associations were statistically significant at \( \alpha = 0.01 \), giving an O:E ratio of 45, \( p \) for difference O:E < 0.000001 (Table 2). At the 0.01\% significance level, 0.456 of the correlations would be expected to be associated by chance, but we found that 1,378 (30\%) were significantly associated at \( \alpha = 0.0001 \), giving an O:E ratio of 3,022, \( p \) for difference O:E < 0.000001.

Figure 1 shows the histogram of magnitudes of age-adjusted partial correlation coefficients that were significant at the \( p < 0.01 \) level. At both \( \alpha = 0.05 \) and \( \alpha = 0.01 \), the median magnitude of the statistically significant age-adjusted partial correlation coefficients was 0.08 (interquartile range, 0.06 to 0.13). At \( \alpha = 0.0001 \), the median magnitude of the statistically significant, age-adjusted partial correlation coefficients was 0.11 (interquartile range, 0.09 to 0.16).

### Associations of Genetic Characteristics with Each Other

The 23 genetic characteristics gave 253 possible pairwise correlations. At the \( p < 0.05 \) level we would expect to be associated by chance and 14 were observed to be associated at this level (O:E ratio = 1.1, \( p = 0.66 \)). At the \( p < 0.01 \) level there were four observed associations compared to 2.53 expected, O:E = 1.6, \( p = 0.33 \).

### Associations of Genetic Characteristics with Nongenetic Characteristics

When we examined the association of each individual SNP with all 96 nongenetic factors, the observed pairwise correlations were similar to expected, with the exception of four variants at the \( \alpha = 0.05 \) level and two variants at \( \alpha = 0.01 \) (Tables 1 and 2). \( APO_{AV} \) was associated with 11 nongenetic characteristics at \( \alpha = 0.05 \) (triglyceride levels, high-density lipoprotein cholesterol, fasting insulin, vitamin C, vitamin E, bilirubin levels, waist:hip ratio, age of the participant’s mother when she died, area level deprivation, age at leaving full-time education, and outdoor ambient temperature in the month and location of birth of the participant), giving an O:E ratio of 2.3, \( p \) for difference O:E = 0.009. The number of significant associations of this variant with nongenetic characteristics at \( \alpha = 0.01 \) was no greater than expected. The hepatic-lipase genetic variant was associated with ten nongenetic characteristics at \( \alpha = 0.05 \) (triglyceride levels, high-density lipoprotein cholesterol, vitamin E, monocytes, phosphate levels, clotting factor VII, claudication, frequency
of consumption of cheese, number of medications, and number of major diseases) giving an O:E of 2.1, \( p \) for difference O:E = 0.02. This variant was also associated with four of these nongenetic characteristics at \( \alpha = 0.01 \) (triglycerides, vitamin E, clotting factor VII, and claudication), giving an O:E ratio at this level of significance of 2.5, \( p \) for difference O:E = 0.02.

The variant in the lipoprotein lipase gene was associated with ten nongenetic characteristics at \( \alpha = 0.05 \) (triglyceride levels, high-density lipoprotein cholesterol, fasting insulin, eosinophils, bilirubin levels, frequency of consumption of fish, age at leaving full-time education, claudication, number of falls, and number of operations), giving an O:E ratio of 2.1, \( p \) for difference O:E = 0.02. This variant was also associated with four of these characteristics at \( \alpha = 0.01 \) (triglycerides, high-density lipoprotein cholesterol, eosinophils, and claudication); O:E ratio 2.5, \( p \) for difference O:E = 0.02. Finally, variants in \( TNFA \) were associated with 11 nongenetic characteristics at \( \alpha = 0.05 \) (trunk length, haemoglobin, mean cell volume, platelets, bilirubin, calcium, phosphate, fibrinogen, plasma viscosity, age of participant’s mother when she died, and EuroQuol quality of life score), giving an O:E of 2.3, \( p \) for difference O:E = 0.009, with the number of associations of this variant with nongenetic characteristics at \( \alpha = 0.01 \) being no greater than expected.

At \( \alpha = 0.0001 \), each variant would be expected to be significantly associated with none (\( n = 0.0096 \)) of the nongenetic variants. However, variation in the \( lactase \) gene was associated with mean outdoor temperature and rainfall in the area and month of the participants birth; variation in \( CETP \) was associated with high-density lipoprotein cholesterol; and variants in \( LPL \) were associated with triglyceride levels. The remaining 20 variants were not associated with any of the nongenetic characteristics at \( p \leq 0.0001 \) (unpublished data).

Considering all 23 SNPs and 96 nongenetic factors (2,208 pairwise correlations), the number of expected significant correlations by chance would be 110, 22.1, and 0.221 at \( p = 0.05, 0.01, \) and \( 0.0001 \), respectively. We observed values similar to this at \( \alpha = 0.05 \) (\( n = 120 \), \( p \) for difference between observed and expected = 0.35) and \( \alpha = 0.01 \) (\( n = 27 \); \( p \) for difference between observed and expected = 0.28), and higher than expected at \( \alpha = 0.0001 \) (\( n = 4 \); \( p \) for difference between observed and expected = 0.00008).

**Discussion**

Over 50% of the pairwise associations between baseline nongenetic characteristics in our study were statistically significant at the 0.05 level; an 11-fold increase from what would be expected, assuming these characteristics were independent. Similar findings were found for statistically significant associations at the 0.01 level (45-fold increase from expected) and the 0.0001 level (3,000-fold increase from expected). This illustrates the considerable difficulty of determining which associations are valid and potentially causal from a background of highly correlated factors, reflecting that behavioural, socioeconomic, and physiological characteristics tend to cluster. This tendency will mean that

### Table 1. Comparison of Observed to Expected Number of Statistically Significant (at \( p = 0.05 \)) Correlations

| Type of Associations Tested | Gene Variant | Number Pairwise Correlations | Expected Number Significant (%) | Observed Number Significant (%) | \( p \) for Null Hypothesis Observed = Expected |
|-----------------------------|--------------|------------------------------|---------------------------------|---------------------------------|-------------------------------------------|
| All 96 nongenetic variables with each other* | LAC1 (rs4988235) | 253 | 12.7 (5) | 14 (5.5) | 0.66 |
| All 23 SNPs with each other | CETP (rs708272) | 96 | 4.8 (5) | 7 (7.3) | 0.34 |
| Each of the following genes with all nongenetic variables | APO_A1 (rs3135506) | 96 | 4.8 (5) | 11 (11.5) | 0.009 |
| | HL (rs1800588) | 96 | 4.8 (5) | 10 (10.4) | 0.02 |
| | LNL (rs5328) | 96 | 4.8 (5) | 11 (11.5) | 0.009 |
| | LTA (rs1041981) | 96 | 4.8 (5) | 3 (3.1) | 0.64 |
| | LGAL (rs72911467) | 96 | 4.8 (5) | 4 (4.2) | 1.00 |
| | LPL (rs1800629) | 96 | 4.8 (5) | 2 (2.1) | 0.24 |
| | PTGS2 (rs20417) | 96 | 4.8 (5) | 6 (6.2) | 0.48 |
| | ESR1 (rs2234693) | 96 | 4.8 (5) | 6 (6.2) | 0.48 |
| | MTHFR (rs1801133) | 96 | 4.8 (5) | 1 (1.0) | 0.10 |
| | MEF2A (rs3730059) | 96 | 4.8 (5) | 2 (2.1) | 0.24 |
| | ADIPOQ (rs1501299) | 96 | 4.8 (5) | 5 (5.2) | 0.81 |
| | PPAR (rs854541) | 96 | 4.8 (5) | 4 (4.2) | 1.00 |
| | GCK (rs1799984) | 96 | 4.8 (5) | 6 (6.2) | 0.48 |
| | ACE (rs4343) | 96 | 4.8 (5) | 2 (2.1) | 0.24 |
| | E2F2 (rs2071307) | 96 | 4.8 (5) | 3 (3.1) | 0.64 |
| | PON1 (rs662) | 96 | 4.8 (5) | 2 (2.1) | 0.24 |
| | GHRL (rs696217) | 96 | 4.8 (5) | 3 (3.1) | 0.64 |
| | PTC (rs713598) | 96 | 4.8 (5) | 3 (3.1) | 0.64 |

*Associations between nongene characteristics were all age adjusted.

**Genes identified by commonly used name and reference SNP (rs) number.

doi:10.1371/journal.pmed.0040352.t001
there will often be high levels of confounding when studying any single factor in relation to an outcome. Given the complexity of such confounding, even after formal statistical adjustment, a lack of data for some confounders, and measurement error in assessed confounders will leave considerable scope for residual confounding [4]. When epidemiological studies present adjusted associations as a reflection of the magnitude of a causal association, they are assuming that all possible confounding factors have been accurately measured and that their relationships with the outcome have been appropriately modelled. We think this is unlikely to be the case in most observational epidemiological studies [26].

Predictably, such confounded relationships will be particularly marked for highly socially and culturally patterned risk factors, such as dietary intake. This high degree of confounding might underlie the poor concordance of observational epidemiological studies that identified dietary factors (such as beta carotene, vitamin E, and vitamin C intake) as protective against cardiovascular disease and cancer, with the findings of randomized controlled trials of these dietary factors [1,27]. Indeed, with 45% of the pairwise associations of nongenetic characteristics being “statistically significant” at the $p < 0.01$ level in our study, and our study being unexceptional with regard to the levels of confounding that will be found in observational investigations, it is clear that the large majority of associations that exist in observational databases will not reach publication. We suggest that those that do achieve publication will reflect apparent biological plausibility (a weak causal criterion [28]) and the interests of investigators. Examples exist of investigators reporting provisional analyses in abstracts—such as antioxidant vitamin intake being apparently protective against future cardiovascular events in women with clinical evidence of cardiovascular disease [29]—but not going on to full publication of these findings, perhaps because randomized controlled trials appeared soon after the presentation of the abstracts [30] that rendered their findings as being unlikely to reflect causal relationships. Conversely, it is likely that the large majority of null findings will not achieve publication, unless they contradict high-profile prior findings, as has been demonstrated in molecular genetic research [31].

The magnitudes of most of the significant correlations between nongenetic characteristics were small (see Figure 1), with a median value at $p = 0.01$ and $p = 0.05$ of 0.08, and it might be considered that such weak associations are unlikely to be important sources of confounding. However, so many associated nongenetic variables, even with weak correlations, can present a very important potential for residual confounding. For example, we have previously demonstrated how 15 socioeconomic and behavioural risk factors, each with weak but statistically independent ($p \leq 0.05$) associations with both vitamin C levels and coronary heart disease (CHD), could together account for an apparent strong protective effect (odds ratio = 0.60 comparing top to bottom quarter of vitamin C distribution) of vitamin C on CHD [32].

The independence of genetic and environmental factors is of importance in other domains of genetic epidemiology, in

| Type of Associations Tested | Gene Variant | Number Pairwise Correlations | Expected Number Significant (%) | Observed Number Significant (%) | $p$ for Null Hypothesis Observed $=$ Expected |
|-----------------------------|--------------|------------------------------|--------------------------------|-------------------------------|---------------------------------------------|
| All 96 nongenetic variables with each other* | CETP (rs708272) | 96 | 0.96 (1) | 0 (0) | 1.00 |
| All 23 SNPs with each other | APOAV (rs135506) | 96 | 0.96 (1) | 2 (2.1) | 0.25 |
| Each of the following genes* with all nongenetic variables | LPL (rs3328) | 96 | 0.96 (1) | 4 (4.2) | 0.02 |
| | TNF-α (rs1800629) | 96 | 0.96 (1) | 1 (1.0) | 0.62 |
| | LTA (rs1041981) | 96 | 0.96 (1) | 1 (1.0) | 0.62 |
| | LCAT (rs4988235) | 96 | 0.96 (1) | 2 (2.1) | 0.25 |

*Associations between nongene characteristics were all age adjusted.

*Genes identified by commonly used name and reference SNP (rs) number.

doi:10.1371/journal.pmed.0040352.t002
addition to that of mendelian randomization. First, case-only studies necessarily assume the independence of genetic and environmental factors in their basic rationale [33,34]. Second, statistical methods for analysing case-control studies in genetic epidemiology can enhance precision by assuming the independence of genetic and environmental factors, as demonstrated by several authors [35–37]. Such approaches have been applied to the analysis of empirical datasets [38]. Conversely, it is commonplace to see statistical adjustment for environmental factors applied to associations between genetic variants and outcomes. This adjustment is probably unnecessary, given the independence of the genetic variants and the environmental factors, and it also provides opportunity for data-derived selection of the adjusted model that provides the strongest evidence for an association with the genetic variant in question. In some cases, indeed, only the adjusted analyses are presented. We suggest that routine adjustment of genetic associations with phenotypic outcomes for potential nongenetic confounding factors is unnecessary and can be misleading.

Three of the authors decided a priori which baseline characteristics were likely to be biologically closely related to each other or likely to be measuring the same underlying characteristic and did not include such variables in the overall correlations. Other investigators might have come up with somewhat different grouping of variables. However, the very high proportion of statistically significant associations at all three levels of significance and the similar findings with sensitivity analyses using different nongenetic characteristics (e.g., total cholesterol instead of triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) suggest that our findings are likely to be replicated even with different opinions about which baseline nongenetic variables should be included in the analyses (provided this selection of nongenetic variables was done a priori within any given dataset). We also deliberately chose only one genetic variant when we had typed several within a gene; this selection ensured there is no association caused by linkage disequilibrium due to close physical proximity of variants. It is possible that pleiotropy or population stratification could generate associations between genetic variants and nongenetic factors, but we do not see strong evidence of this in our study population of United Kingdom (UK) women, very largely of white European origin.

The genetic polymorphisms that we investigated were those that had been assayed in this cohort study. The variants that we have typed to date are those that we (or study collaborators) wish to use in mendelian randomization studies or to replicate previous association studies. Thus, these variants have all been selected on the grounds that there was some evidence that they relate to biological differences between individuals for phenotypes or disease outcomes that we have assessed in this cohort. Therefore, they are a group of variants that will tend to be related to phenotypic differences. Our variants include, for example, the C→T677 MTHFR variant and the SNP that marks the lactase persistence trait, two well-known and widely studied variants with clear biological correlates. The number of associations found with phenotypic variables should, therefore, be higher for our SNPs than for a group of SNPs selected without reference to known function. Four of the chosen variants (lying at the APO_AV, HL, LPL, and TNFA loci) were associated with more phenotypes than expected at either the 0.05 or 0.01 significance level. It is possible that these variants are involved in such a wide range of biological processes that the observations are causal. However, these “positive” findings, particularly those at the 0.05 level, may well simply represent the play of chance and be nonreplicable in future studies. In support of our general hypothesis that in mendelian randomization studies, genetic variants are seldom confounded by phenotypic factors [10], overall we found no more associations with phenotypes than would be expected by chance at the 0.05 or 0.01 level.

At a more realistic p-value threshold for genetic association...
studies (p ≤ 0.0001), only four (0.18%) out of 2,208 associations of 23 genetic variants with 96 nongenetic characteristics were statistically significant. Although this is greater than the number (0.22) expected by chance, the proportion of statistically significant associations of genotype with nongenetic characteristics is considerably smaller than the proportion of significant associations between nongenetic characteristics (0.18% versus 30%) at this level of significance. It is difficult to believe that all or a substantial proportion of the 1,378 statistically significant associations (at p ≤ 0.0001) between two nongenetic characteristics are truly causal, whereas the four associations of genetic variants with nongenetic factor associations at this level of significance may well be real. The association of variants in lactase with mean outdoor temperature and rainfall for the area and month of birth of the participant is likely to reflect the established population stratification for this variant [39,40]. Since the allele frequency of this variant is known to vary by ancestral geography, we would take this into account in any mendelian randomization studies of this variant. The other two associations—CETP with high-density lipoprotein cholesterol [41–43]; and LPL with triglycerides [44]—reflect the biological actions of these genes.

Our findings provide reassuring evidence that utilizing genetic variants in mendelian randomization studies is generally a legitimate strategy. Furthermore, statistical methods that assume independence of genetic and environmental factors are also legitimate in many circumstances [33–38]. Our findings are concordant with the demonstration that a large number of genetic variants were unrelated to participation or nonparticipation in a series of case-control studies [45]; with occasional reports of gene–environment independence that have focused on a limited number of variants and environmental factors [46]; with the very similar distribution of allelic frequencies among blood donors and a representative population sample in the UK [47] and with a detailed review of gene–environment correlations in behavioural genetics [48]. We have demonstrated a fundamental difference in the degree of confounding of genetic variants and other variables. This difference can be exploited by using genetic variants as exposure indicators to study the effects on common diseases of modifiable risk factors that are too heavily confounded to be studied robustly through conventional observational epidemiological approaches [10].

Supporting Information

Table S1. Phenotypes Included in Primary Analyses
Found at doi:10.1371/journal.pmed.0040352.sd001 (38 KB DOC).

Table S2. Constituent Phenotypes Used in the Main Analysis
Found at doi:10.1371/journal.pmed.0040352.sd002 (27 KB DOC).

Table S3. Genotypes Used in the Main Analyses
Found at doi:10.1371/journal.pmed.0040352.sd003 (46 KB DOC).

Text S1. Phenotypes Included in Main Analyses
Found at doi:10.1371/journal.pmed.0040352.sd001 (35 KB DOC).

Acknowledgments

The British Women’s Heart and Health Study is funded by the UK Department of Health Policy Research Programme and the British Heart Foundation. DAL is funded by a UK Department of Health Career Scientist Award, and NT by a UK Medical Research Council Studentship. The views expressed in this paper are those of the authors and not necessarily those of the Department of Health, British Heart Foundation, or Medical Research Council.

Author contributions. GDS, SE, and ID designed the study. DAL and RH analyzed the data. DAL and SE enrolled patients. GDS, DAL, RH, NT, ID, and SE contributed to writing the paper.

References

1. Davey Smith G, Ebrahim S (2001) Mendelian randomization— is it time to call it a day? Int J Epidemiol 30: 1–11.
2. Lawlor DA, Davey Smith G, Bruckdorfer KR, Kundu D, Ebrahim S (2004) Those pseudo-vendettas: what can we learn from the differences between observational versus randomized trial evidence? Lancet 363: 1724–1727.
3. Vandenbroucke JP (2004) When are observational studies as credible as randomized trials? Lancet 363: 1728–1731.
4. Phillips AN, Davey Smith G (1992) Bias in relative odds estimation owing to imprecise measurement of correlated exposures. Stat Med 11: 953–961.
5. Davey Smith G, Phillips AN (1992) Confounding in epidemiological studies: why ‘independent’ effects may not be all they seem. BMJ 305: 757–759.
6. Rothman KJ. Greenland S, editors (1998) Modern epidemiology. 2nd edition. Philadelphia (Pennsylvania): Lippincott/Raven. 738 p.
7. Sterne J, Davey Smith G (2001) Sifting the evidence—what’s wrong with significance tests? BMJ 322: 226–231.
8. Sterne JAC, Egger M, Davey Smith G (2003) Investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101–105.
9. Macleod J, Davey Smith G, Hesplop M, Metcalfe C, Carroll D, et al. (2002) Psychological stress and cardiovascular disease: empirical demonstration of bias in a prospective observational study on Scottish men. BMJ 324: 1247–1251.
10. Davey Smith G, Ebrahim S (2003) ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1–22.
11. Didelez V, Sheehan NA (2007) Mendelian randomization: why epidemiology needs a formal language for causality. In: Russo F, Williamson J, editors. Causality and probability in the sciences. London: College Publications.
12. Lewis SJ, Davey Smith G (2005) Alcohol, ALDH2, and esophageal cancer: a meta-analysis which illustrates the potentials and limitations of a MR approach. Cancer Epidemiol Biomarkers Prev 14: 1967–1971.
13. Casas JP, Shah T, Cooper J, Hare F, McMahon AD, et al. (2006) Insight into the nature of the CRP-coronary event association using mendelian randomization. Int J Epidemiol 35: 922–931.
14. Keavney B, Danesh J, Parish S, Palmer A, Clark S, et al. (2006) Fibrogen and coronary heart disease: test of causality by ‘mendelian randomization.’ Int J Epidemiol 35: 935–943.
15. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day INM, et al. (2005) C-reactive protein and its role in metabolic syndrome: mendelian randomization study. Lancet 366: 1954–1959.
16. Davey Smith G, Harbord R, Milton J, Ebrahim S, Sterne JAC (2005) Does elevated plasma fibrinogen increase the risk of coronary heart disease?: Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 25: 2978–2983.
17. Davey Smith G (2007) Capitalizing on mendelian randomization to assess the effects of treatments. J R Soc Med 100: 432–435.
18. Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, et al. (2006) Limits to causal inference based on mendelian randomization, a comparison with randomized controlled trials. Am J Epidemiol 165: 397–403.
19. Wacholder S, Rothman N, Caporaso N, et al. (2002) Countepoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomark Prev 11: 515–529.
20. Thomas DC, Witte JS. (2002) Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomark Prev 11: 505–509.
21. Thomas DC, Witte JS. (2002) Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomark Prev 11: 505–509.
22. Caridon LR, Palmer LJ (2003) Wagging the dog? Population stratification and apolipoprotein alllic association. Lancet 361: 2099–2104.
23. Hoggart CJK, Parra EJ, Shriver MD, Bonilla C, Kattah RA, et al. (2003) Control of confounding of genetic associations in stratified populations. Am J Hum Genet 72: 1492–1504.
24. Epstein MP, Allen AS, Satten GA (2007) A simple and improved correction for population stratification in case-control studies. Am J Hum Genet 80: 921–930.
25. Davey Smith G, Lawlor D, Harbord R, Timpson N, Rumley A, et al. (2005) Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 25: 1051–1056.
26. Phillips A, Davey Smith G (1991) How independent are ‘independent’ effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 44: 1223–1231.
27. Davey Smith G, Ebrahim S (2002) Data dredging, bias, or confounding [editorial]. BMJ 325: 1437–1438.
28. Davey Smith G, Phillips AN, Neaton J D. (1992) Smoking as ‘independent’
risk factor for suicide: illustration of an artifact from observational epidemiology? Lancet 340: 709–12
29. Manson JE, Stampfer MJ, Willett WC (1995) Antioxidant vitamins and the secondary prevention of cardiovascular disease in women [abstract]. Circulation 88: 170–172.
30. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029–1035.
31. Ioannidis JPA, Trikalinos TA (2005) Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. J Clin Epidemiol 58: 545–549.
32. Lawlor DA, Davey Smith G, Bruckdorfer KR, Tilling K, Ebrahim S (2004) Observational versus randomized trial evidence [correspondence]. Lancet 364: 754–755.
33. Khoury MJ, Flanders WD (1996) Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with nonparametric assessment. Am J Epidemiol 144: 207–213.
34. Shin J-H, McNeney B, Graham J (2007) Case-control inference of interactions between genetic and nongenetic risk factors under assumptions on their distribution. Stat Appl Genet Mol Biol 6: 1–41.
35. Umbach DM, Weinberg CR (1994) Designing and analysing case-control studies to exploit independence of genotype and exposure. Stat Med 13: 1731–1743.
36. Chatterjee N, Carroll RJ (2005) Semiparametric maximum likelihood estimation exploiting gene-environment independence in case-control studies. Biometrika 92: 399–418.
37. Chatterjee N, Kalaylioglu Z, Carroll RJ (2005) Exploiting gene-environment independence in family-based case-control studies: increased power for detecting associations, interactions and joint effects. Genet Epidemiol 28: 135–156.
38. Modan B, Hartege PK, Hirsh-Yechezkel G, Chetrit A, Lubin F, et al. (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345: 235–40.
39. Davey Smith G, Lawlor DA, Timpson NJ, Bahan J, Kissling M, et al. (2007) Lactase persistence related genetic variant: population substructure, milk drinking and health outcomes. Eur J Hum Genet. In press.
40. Campbell DH, Ogburn EL, Lunetta KL, Lyon HE, Freedman ML, et al. (2005) Demonstrating stratification in a European American population. Nat Genet 37: 868–872.
41. Thompson JF, Lira ME, Durham LK, Clark RW, Bamberger MJ, et al. (2003) Polymorphisms in the CETP gene and association with CETP mass and HDL levels. Atherosclerosis 167: 195–204.
42. Dachet C, Poirier O, Camben F, Chapman J, Rouis M, et al. (2000) New functional promoter polymorphism, CETP-Δ92, incholesterol ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 20: 507–515.
43. Or doväs J, Cupples L, C orellâ D, Otto J, Os good D, et al. (2000) Association of cholest erol ester transfer protein-TaqB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 20: 1323–1329.
44. Georges JL, Regis-Bailey A, Salah D, Rakotovao R, Siest G, et al. (1996) Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. Genet Epidemiol 13: 139–152.
45. Bhati P, Sigurdsson AJ, Wang SS, Chen J, Rothman N, et al. (2005) Genetic variation and willingness to participate in epidemiological research: data from three studies. Cancer Epidemiol Biomarkers Prev 14: 2449–2453.
46. Smits KM, Benhamou S, Garte S, Weigenberg MP, Alamanos Y, et al. (2004) Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. Int J Cancer 110: 266–270.
47. The Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,500 cases of seven common disease and 3,000 shared controls. Nature 447: 661–678.
48. Jaffe SR, Price TS (2007) Gene-environment correlations: a review of the evidence and implication for prevention of mental illness. Mol Psychiatry 12: 432–442.